Skip to main content
logo

Sawai Group Holdings Co., Ltd. (TYO:4887)

Japan flag Japan · Delayed Price · Currency is JPY
1,597.00
+22.00 (1.40%)
Sep 8, 2026, 2:30 PM JST
Market Cap181.89B -21.0%
Revenue (ttm)203.79B +4.9%
Net Income7.98B -35.4%
EPS68.85 -32.8%
Shares Out 115.49M
PE Ratio19.12
Forward PE9.96
Dividend56.00 (3.55%)
Ex-Dividend DateSep 29, 2026
Volume649,500
Open1,570.00
Previous Close1,575.00
Day's Range1,568.00 - 1,610.00
52-Week Range1,550.50 - 2,447.00
Beta0.02
AnalystsBuy
Price Target2,182.22 (+36.65%)
Earnings DateAug 10, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the manufacture and sale of pharmaceuticals. The company offers generic drugs in various dosage forms for therapeutic areas comprising cardiovascular and antibiotic preparations, central nervous system drugs, other metabolic drugs, digestive tract medicines, blood and body fluid medications, allergy medications, respiratory medicine, vitamin supplements, oncology drugs, chemotherapeutic agents, genitourinary and anal drugs, and others. It sells its generic drugs through dist... [Read more]

Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Founded 1929
Employees 3,630
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4887
Full Company Profile

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 4887 stock is "Buy." The 12-month stock price target is ¥2,182, which is an increase of 36.65% from the latest price.

Price Target
¥2,182
(36.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Sawai Group Holdings Transcript: Transcript

Revenue and profits grew year-over-year, driven by higher sales prices and lifted shipment restrictions, while net income was boosted by a one-time gain from a U.S. business sale. FY 2025 guidance projects continued revenue and profit growth, despite cost pressures and industry reforms.

10 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue rose 6.7% year-on-year, but core operating profit fell 3.6% while operating profit surged due to the absence of litigation provisions. FY 2026 forecasts call for revenue and profit growth, with strong new product sales and increased production capacity.

14 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue and profits grew year-over-year, aided by a U.S. affiliate share sale and improved unit prices. The outlook targets further profit growth via new launches and cost controls, while a major share buyback and dividend hike were announced.

14 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue grew 12.5% year-over-year, but operating profit fell 27.4% due to a patent settlement. Core operating profit rose 9.5%, and full-year guidance was revised as production targets became harder to achieve.

14 days ago - Transcripts

Sawai Group Holdings Quarterly report: Q1 2027

Sawai Group Holdings has published its Q1 2027 quarterly earnings report on August 10, 2026.

4 weeks ago - Filings

Sawai Group Holdings Slides: Q1 2027

Sawai Group Holdings has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.

4 weeks ago - Filings